California based pharmaceutical company Orexigen Therapeutics has announced that it will be stopping the development of its diet pill in the American market citing "unprecedented" demands by the health regulators over the pill's safety.
The company said that it will now be concentrating on getting the approval for its diet pill, known as Contrave and another drug candidate, Empatic, in other international markets.
AdvertisementThe US Food and Drug Administration had refused to approve the drug back in February after concerns were raised that it could affect the heart.
Orexigen said that the FDA wanted it to conduct a large study looking into whether the drug actually affected the heart and the company said that the study would have unveiled information that was not necessary for its approval.
P'The Obedient Wife Club' Launched To Curb Divorce, Domestic Violence Animas’ Glucose Monitoring Insulin Pump Receives EU Green Signal M
You May Also Like